Clinical Focus

Previous Articles     Next Articles

Safety analysis of  rivaroxaban in  perioperative period of pacemaker implantation

  

  1. 1.Department of Cardiology, Lanzhou University Second Hospital,Lanzhou 730030,China;
    2.Department of Cardiology, Gansu Provincial Traditional Chinese Medicine Hospital,Lanzhou 730050,China;
    3.Department of Cardiology, Tianjin Fourth Hospital,Tianjin 300140,China
  • Received:2016-03-17 Online:2016-06-05 Published:2016-06-06
  • Contact: Correspondingauthor:Xu Yixian,Email:911454838@qq.com

Abstract:

ObjectiveTo observe the incidence of perioperative pocket hemorrhage of pacemaker in patients with oral anticoagulant rivaroxaban, and to provide evidence for optimizing perioperative anticoagulation therapy. MethodsThe clinical data of patients with pacemaker implantation were retrospectively analyzed, and the patients were divided into two groups according to different anticoagulation therapies.  Group A patients (n=80) received longterm anticoagulant treatment with warfarin, INR adjusted to 1.52.0 before implantation, warfarin was not suspended  in preoperative period. In  group B(n=72),patients received anticoagulant treatment with rivaroxaban  constantly. The incidence of pocket hemorrhage was compared after pacemaker implantation in two groups. ResultsA total of 152 patients with anticoagulation therapies  were operated pacemaker implantation. Group A showed mild pocket bleeding in 4 cases, moderate pocket bleeding in 2 cases,severe pocket bleeding in 1 case.Group B had mild pocket bleeding in 4 cases, moderate pocket bleeding in 1 case,but no severe pocket bleeding. There was no significant difference  in pocket bleeding  between two groups (P>0.05). ConclusionIn  perioperative period of pacemaker implantation, the constant application of rivaroxaban did not increase the risk of bleeding compared with warfarin.

Key words: pace maker, artificial, blood loss, surgical, warfarin, rivaroxaban